Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells

Leukemia

Volumn 27, Issue 5, 2013, Pages 1201-1204

  White, D L ^a,b,c   Eadie, L N ^a,b,c   Saunders, V A ^a,b   Hiwase, D K ^a,b,c   Hughes, T P ^a,b,c  

^a SA Pathology ^*  (Australia)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; IC 50; LETTER; LEUKEMIA CELL; PRIORITY JOURNAL;

BENZAMIDES; DRUG INTERACTIONS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTON PUMP INHIBITORS; PYRIMIDINES;

EID: 84877622305     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.295     Document Type: Letter

References (17)

1. White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520-2526.
2. White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007; 25: 4445-4451.
3. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. OCT- 1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697-704.
4. Yin OQ, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 2010; 50: 960-967.
5. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004; 96: 1702-1713.
6. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 551-557.
7. Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005; 156: 319-329.
8. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401-408.
9. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A et al. Highaffinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65: 1485-1495.
10. Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother 2005; 39: 162-164.
11. Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 2012; 70: 345-350.
12. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronicphase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010; 28: 2761-2767.
13. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-978.
14. Geus WP, Mathot RA, Mulder PG, Lamers CB. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40mg during repeated oral administration in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther 2000; 14: 1057-1064.
15. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-958.
16. Andersson T, Holmberg J, Rohss K, Walan A. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45: 369-375.
17. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8(Suppl 1): S21-S25.